Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy|
|Citation:||Thorax, 2021; 76(7):733-736|
|Shakti D Shukla, Steven L Taylor, Peter G Gibson, Daniel Barker, John W Upham, Ian A Yang ... et al.|
|Abstract:||Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced <jats:italic>Haemophilus influenzae</jats:italic> load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.|
|Rights:||© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.